Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...

NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. The evolving NF1 landscape highlights how innovation ...

Summary. Merck KGaA agreed to acquire SpringWorks Therapeutics for $47 per share in cash or for $3.9 billion; the acquisition brings in drugs of OGSIVEO and GOMEKLI to big pharma's pipeline.

Merck KGaA will acquire SpringWorks Therapeutics, a US biopharmaceutical company focused on developing treatments for rare tumors. 1 According to a press release from SpringWorks, this will allow the ...

SpringWorks shares surged 21% between April 21 and Thursday, from $37.06 to $44.93, before dipping 0.5% to $44.72 on Friday—a day after Merck KGaA re-confirmed it was in late-stage discussions ...

German pharmaceutical company Merck announced Monday that it has reached an agreement to acquire US-based SpringWorks Therapeutics for $3.9 billion, a move aimed at strengthening its oncology ...